Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHN-010 in advanced solid tumors
NCT06457997Phase 1Terminated
- Sponsor
- Pheon Therapeutics
- Start
- Jul 2024
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PHN-010 in lung cancer, colon cancer, endometrial cancer (EC) and 2 more, sponsored by Pheon Therapeutics. Primary endpoints: Dose Limiting Toxicities at 18 months, Adverse Events and Serious Adverse Events at 18 months and 2 more. Started Jul 2024; status: terminated.
02
Drugs
PHN-010
03
Conditions
lung cancercolon cancerendometrial cancer (EC)ovarian cancerCervical Cancer (CC)
Beyond the preview
Go deeper on NCT06457997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06457997.